J Dillner
Overview
Explore the profile of J Dillner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
2996
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bzhalava D, Bray F, Storm H, Dillner J
Br J Cancer
. 2010 Nov;
104(1):178-80.
PMID: 21081931
Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumour of the skin that has been associated with a new tumour virus, the MCC polyomavirus. Methods: To investigate whether MCC...
12.
Dillner J, Arbyn M, Unger E, Dillner L
Clin Exp Immunol
. 2010 Nov;
163(1):17-25.
PMID: 21062269
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18,...
13.
Majewski S, Bosch F, Dillner J, Iversen O, Kjaer S, Munoz N, et al.
J Eur Acad Dermatol Venereol
. 2009 May;
23(10):1147-55.
PMID: 19453788
Background: Quadrivalent human papillomavirus (HPV types 6/11/16/18) L1 VLP vaccine is highly effective in preventing HPV 6/11/16/18-related cervical and external genital disease. Herein, we evaluated the impact of the quadrivalent...
14.
Tegnell A, Dillner J, Andrae B
Euro Surveill
. 2009 Feb;
14(6).
PMID: 19215721
The Swedish National Board of Health and Welfare (NBH) decided that a vaccine that protects against cervical cancer caused by human papillomavirus (HPV) should be included in the childhood vaccination...
15.
Ryding J, French K, Naucler P, Barnabas R, Garnett G, Dillner J
Vaccine
. 2008 Aug;
26(41):5263-8.
PMID: 18692109
We have performed a serological survey of HPV type 16-antibody prevalence by age and sex in Sweden and used it as a basis for modelling the optimal vaccination strategies in...
16.
Bleeker M, Heideman D, Snijders P, Horenblas S, Dillner J, Meijer C
World J Urol
. 2008 Jul;
27(2):141-50.
PMID: 18607597
Objectives: Penile cancer is a disease with a high morbidity and mortality. Its prevalence is relatively rare, but the highest in some developing countries. Insight into its precursor lesions, pathogenesis...
17.
Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, et al.
Gut
. 2008 Apr;
57(10):1393-7.
PMID: 18436577
Background And Aims: Anti-alpha4 integrin therapy with natalizumab is efficacious in refractory Crohn's disease and in multiple sclerosis, but carries an estimated 1/1000 risk of progressive multifocal leukoencephalopathy (PML) caused...
18.
Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson B, et al.
Br J Cancer
. 2007 Jun;
97(1):129-32.
PMID: 17551490
We followed a population-based cohort of 5696 women, 32-38 years of age, by registry linkage with cytology and pathology registries during a mean follow-up time of 4.1 years to assess...
19.
Dillner J, Arbyn M, Dillner L
Clin Exp Immunol
. 2007 Apr;
148(2):199-207.
PMID: 17437418
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with more...
20.
Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J
J Gen Virol
. 2007 Feb;
88(Pt 3):792-802.
PMID: 17325351
Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the...